Avidity Biosciences (RNA) Stock Forecast, Price Target & Predictions
RNA Stock Forecast
Avidity Biosciences stock forecast is as follows: an average price target of $54.50 (represents a 21.60% upside from RNA’s last price of $44.82) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
RNA Price Target
RNA Analyst Ratings
Avidity Biosciences Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 24, 2024 | Corinne Johnson | Goldman Sachs | $59.00 | $43.50 | 35.63% | 31.64% |
Jun 12, 2024 | Yanan Zhu | Wells Fargo | $50.00 | $28.92 | 72.89% | 11.56% |
Avidity Biosciences Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 2 |
Avg Price Target | - | $59.00 | $54.50 |
Last Closing Price | $44.82 | $44.82 | $44.82 |
Upside/Downside | -100.00% | 31.64% | 21.60% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 30, 2024 | Goldman Sachs | Buy | Buy | Hold |
Oct 21, 2024 | Needham | Buy | Buy | Hold |
Oct 21, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
Oct 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
Oct 03, 2024 | Goldman Sachs | Buy | Buy | Hold |
Sep 24, 2024 | Goldman Sachs | - | Buy | Initialise |
Sep 16, 2024 | Evercore Partners | Underperform | Underperform | Hold |
Sep 16, 2024 | Needham | Buy | Buy | Hold |
Aug 28, 2024 | Barclays | - | Overweight | Initialise |
Aug 12, 2024 | Needham | Buy | Buy | Hold |
Avidity Biosciences Financial Forecast
Avidity Biosciences Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.82M | $2.32M | $2.23M | $2.77M | $2.48M | $2.18M | $1.79M | $1.85M | $2.16M | $2.61M | $2.70M | $2.14M | $1.75M | $1.54M |
Avg Forecast | $4.33M | $4.02M | $3.73M | $3.46M | $4.03M | $4.03M | $3.53M | $3.53M | $2.40M | $4.07M | $2.63M | $2.57M | $12.21M | $2.21M | $2.14M | $2.04M | $2.16M | $2.13M | $2.11M | $1.90M | $2.17M | $2.13M | $1.94M | $1.00M | $838.75K | $575.00K | $700.00K |
High Forecast | $4.33M | $4.02M | $3.73M | $3.46M | $4.03M | $4.03M | $3.53M | $3.53M | $2.40M | $4.07M | $2.63M | $2.57M | $23.86M | $2.21M | $2.14M | $2.04M | $2.16M | $2.13M | $2.11M | $1.90M | $2.17M | $2.13M | $1.94M | $1.00M | $838.75K | $575.00K | $700.00K |
Low Forecast | $4.33M | $4.02M | $3.73M | $3.46M | $4.03M | $4.03M | $3.53M | $3.53M | $2.40M | $4.07M | $2.63M | $2.57M | $570.98K | $2.21M | $2.14M | $2.04M | $2.16M | $2.13M | $2.11M | $1.90M | $2.17M | $2.13M | $1.94M | $1.00M | $838.75K | $575.00K | $700.00K |
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.27% | 1.08% | 1.09% | 1.28% | 1.17% | 1.03% | 0.94% | 0.85% | 1.02% | 1.35% | 2.70% | 2.55% | 3.04% | 2.20% |
Avidity Biosciences EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-58.06M | $-52.63M | $-57.60M | $-53.23M | $-44.56M | $-45.98M | $-34.15M | $-38.33M | $-29.10M | $-26.21M | $-23.74M | $-16.16M | $-11.34M | $-10.35M |
Avg Forecast | $-4.33M | $-4.02M | $-3.73M | $-3.46M | $-4.03M | $-4.03M | $-3.53M | $-3.53M | $-2.40M | $-4.07M | $-2.63M | $-2.57M | $-12.21M | $-2.21M | $-2.14M | $-2.04M | $-2.16M | $-2.13M | $-2.11M | $-37.46M | $-2.17M | $-2.13M | $-1.94M | $-20.35M | $-838.75K | $-575.00K | $-29.11M |
High Forecast | $-4.33M | $-4.02M | $-3.73M | $-3.46M | $-4.03M | $-4.03M | $-3.53M | $-3.53M | $-2.40M | $-4.07M | $-2.63M | $-2.57M | $-570.98K | $-2.21M | $-2.14M | $-2.04M | $-2.16M | $-2.13M | $-2.11M | $-29.97M | $-2.17M | $-2.13M | $-1.94M | $-16.28M | $-838.75K | $-575.00K | $-23.29M |
Low Forecast | $-4.33M | $-4.02M | $-3.73M | $-3.46M | $-4.03M | $-4.03M | $-3.53M | $-3.53M | $-2.40M | $-4.07M | $-2.63M | $-2.57M | $-23.86M | $-2.21M | $-2.14M | $-2.04M | $-2.16M | $-2.13M | $-2.11M | $-44.95M | $-2.17M | $-2.13M | $-1.94M | $-24.41M | $-838.75K | $-575.00K | $-34.93M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.23% | 24.54% | 28.17% | 24.64% | 20.97% | 21.76% | 0.91% | 17.62% | 13.69% | 13.53% | 1.17% | 19.27% | 19.72% | 0.36% |
Avidity Biosciences Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-52.36M | $-47.02M | $-47.19M | $-47.72M | $-42.27M | $-44.47M | $-34.01M | $-38.53M | $-29.27M | $-26.34M | $-23.83M | $-16.26M | $-11.41M | $-10.74M |
Avg Forecast | $-117.10M | $-117.14M | $-109.49M | $-109.53M | $-84.47M | $-83.67M | $-78.70M | $-78.06M | $-81.02M | $-76.07M | $-80.86M | $-85.13M | $-70.50M | $-80.91M | $-84.80M | $-89.65M | $-95.08M | $-99.79M | $-82.26M | $-38.09M | $-74.58M | $-72.39M | $-76.19M | $-20.44M | $-36.62M | $-39.03M | $-29.69M |
High Forecast | $-117.10M | $-117.14M | $-109.49M | $-109.53M | $-84.47M | $-83.67M | $-78.70M | $-78.06M | $-81.02M | $-53.92M | $-80.86M | $-85.13M | $9.14M | $-80.91M | $-84.80M | $-89.65M | $-95.08M | $-99.79M | $-82.26M | $-30.47M | $-74.58M | $-72.39M | $-76.19M | $-16.35M | $-36.62M | $-39.03M | $-23.75M |
Low Forecast | $-117.10M | $-117.14M | $-109.49M | $-109.53M | $-84.47M | $-83.67M | $-78.70M | $-78.06M | $-81.02M | $-90.51M | $-80.86M | $-85.13M | $-114.89M | $-80.91M | $-84.80M | $-89.65M | $-95.08M | $-99.79M | $-82.26M | $-45.70M | $-74.58M | $-72.39M | $-76.19M | $-24.53M | $-36.62M | $-39.03M | $-35.63M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.55% | 0.53% | 0.50% | 0.42% | 0.54% | 0.89% | 0.52% | 0.40% | 0.35% | 1.17% | 0.44% | 0.29% | 0.36% |
Avidity Biosciences SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $13.73M | $12.28M | $12.06M | $10.38M | $10.09M | $8.69M | $8.57M | $7.43M | $6.61M | $6.27M | $5.88M | $4.82M | $3.76M | $2.92M |
Avg Forecast | $14.32M | $13.28M | $12.32M | $11.43M | $13.33M | $13.33M | $11.69M | $11.69M | $7.95M | $13.46M | $8.68M | $8.50M | $40.39M | $7.32M | $7.09M | $6.76M | $7.14M | $7.03M | $6.99M | $6.28M | $7.19M | $7.03M | $6.41M | $3.31M | $2.77M | $1.90M | $2.32M |
High Forecast | $14.32M | $13.28M | $12.32M | $11.43M | $13.33M | $13.33M | $11.69M | $11.69M | $7.95M | $13.46M | $8.68M | $8.50M | $78.90M | $7.32M | $7.09M | $6.76M | $7.14M | $7.03M | $6.99M | $6.28M | $7.19M | $7.03M | $6.41M | $3.31M | $2.77M | $1.90M | $2.32M |
Low Forecast | $14.32M | $13.28M | $12.32M | $11.43M | $13.33M | $13.33M | $11.69M | $11.69M | $7.95M | $13.46M | $8.68M | $8.50M | $1.89M | $7.32M | $7.09M | $6.76M | $7.14M | $7.03M | $6.99M | $6.28M | $7.19M | $7.03M | $6.41M | $3.31M | $2.77M | $1.90M | $2.32M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.88% | 1.73% | 1.78% | 1.45% | 1.44% | 1.24% | 1.36% | 1.03% | 0.94% | 0.98% | 1.78% | 1.74% | 1.98% | 1.26% |
Avidity Biosciences EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.71 | $-0.66 | $-0.67 | $-0.83 | $-0.80 | $-0.89 | $-0.70 | $-1.63 | $-0.68 | $-0.70 | $-0.64 | $-0.43 | $-0.30 | $-1.25 |
Avg Forecast | $-1.10 | $-1.10 | $-1.02 | $-1.02 | $-0.79 | $-0.78 | $-0.74 | $-0.73 | $-0.76 | $-0.71 | $-0.76 | $-0.80 | $-0.66 | $-0.76 | $-0.79 | $-0.84 | $-0.89 | $-0.93 | $-0.77 | $-0.80 | $-0.70 | $-0.68 | $-0.71 | $-0.56 | $-0.34 | $-0.36 | $-0.36 |
High Forecast | $-1.10 | $-1.10 | $-1.02 | $-1.02 | $-0.79 | $-0.78 | $-0.74 | $-0.73 | $-0.76 | $-0.50 | $-0.76 | $-0.80 | $0.09 | $-0.76 | $-0.79 | $-0.84 | $-0.89 | $-0.93 | $-0.77 | $-0.80 | $-0.70 | $-0.68 | $-0.71 | $-0.56 | $-0.34 | $-0.36 | $-0.36 |
Low Forecast | $-1.10 | $-1.10 | $-1.02 | $-1.02 | $-0.79 | $-0.78 | $-0.74 | $-0.73 | $-0.76 | $-0.85 | $-0.76 | $-0.80 | $-1.07 | $-0.76 | $-0.79 | $-0.84 | $-0.89 | $-0.93 | $-0.77 | $-0.80 | $-0.70 | $-0.68 | $-0.71 | $-0.56 | $-0.34 | $-0.36 | $-0.36 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.83% | 0.80% | 0.93% | 0.86% | 1.16% | 0.88% | 2.34% | 1.00% | 0.98% | 1.15% | 1.26% | 0.82% | 3.46% |
Avidity Biosciences Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
BDTX | Black Diamond Therapeutics | $2.99 | $14.75 | 393.31% | Buy |
RLAY | Relay Therapeutics | $5.85 | $19.40 | 231.62% | Buy |
PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
ARVN | Arvinas | $26.80 | $71.82 | 167.99% | Buy |
DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
SWTX | SpringWorks Therapeutics | $30.94 | $67.33 | 117.61% | Buy |
CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
IGMS | IGM Biosciences | $15.69 | $20.33 | 29.57% | Buy |
RNA | Avidity Biosciences | $44.82 | $54.50 | 21.60% | Buy |
PTGX | Protagonist Therapeutics | $46.76 | $50.00 | 6.93% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
RNA Forecast FAQ
Is Avidity Biosciences a good buy?
Yes, according to 8 Wall Street analysts, Avidity Biosciences (RNA) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of RNA's total ratings.
What is RNA's price target?
Avidity Biosciences (RNA) average price target is $54.5 with a range of $50 to $59, implying a 21.60% from its last price of $44.82. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Avidity Biosciences stock go up soon?
According to Wall Street analysts' prediction for RNA stock, the company can go up by 21.60% (from the last price of $44.82 to the average price target of $54.5), up by 31.64% based on the highest stock price target, and up by 11.56% based on the lowest stock price target.
Can Avidity Biosciences stock reach $70?
RNA's average twelve months analyst stock price target of $54.5 does not support the claim that Avidity Biosciences can reach $70 in the near future.
What are Avidity Biosciences's analysts' financial forecasts?
Avidity Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $15.13M (high $15.13M, low $15.13M), average EBITDA is $-15.129M (high $-15.129M, low $-15.129M), average net income is $-325M (high $-325M, low $-325M), average SG&A $50.03M (high $50.03M, low $50.03M), and average EPS is $-3.038 (high $-3.038, low $-3.038). RNA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $15.53M (high $15.53M, low $15.53M), average EBITDA is $-15.53M (high $-15.53M, low $-15.53M), average net income is $-453M (high $-453M, low $-453M), average SG&A $51.36M (high $51.36M, low $51.36M), and average EPS is $-4.239 (high $-4.239, low $-4.239).
Did the RNA's actual financial results beat the analysts' financial forecasts?
Based on Avidity Biosciences's last annual report (Dec 2023), the company's revenue was $9.56M, which missed the average analysts forecast of $18.61M by -48.64%. Apple's EBITDA was $-236M, beating the average prediction of $-18.614M by 1165.69%. The company's net income was $-212M, missing the average estimation of $-326M by -34.87%. Apple's SG&A was $54.19M, missing the average forecast of $61.56M by -11.97%. Lastly, the company's EPS was $-2.91, missing the average prediction of $-3.048 by -4.51%. In terms of the last quarterly report (Sep 2023), Avidity Biosciences's revenue was $2.82M, beating the average analysts' forecast of $2.21M by 27.30%. The company's EBITDA was $-58.059M, beating the average prediction of $-2.214M by 2522.83%. Avidity Biosciences's net income was $-52.358M, missing the average estimation of $-80.909M by -35.29%. The company's SG&A was $13.73M, beating the average forecast of $7.32M by 87.53%. Lastly, the company's EPS was $-0.71, missing the average prediction of $-0.757 by -6.17%